Page last updated: 2024-12-08

sclareol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sclareol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sclareol : A labdane diterpenoid that is labd-14-ene substituted by hydroxy groups at positions 8 and 13. It has been isolated from Salvia sclarea. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
SalviagenusA genus in the mint family (LAMIACEAE).[MeSH]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]

Cross-References

ID SourceID
PubMed CID163263
CHEMBL ID294740
CHEBI ID9053
SCHEMBL ID873931
MeSH IDM0192569

Synonyms (59)

Synonym
labd-14-ene-8,13-diol, (13r)-
1-naphthalenepropanol, decahydro-alpha-ethenyl-2-hydroxy-alpha,2,5,5,8a-pentamethyl-, (1r-(1-alpha(r*),2-beta,4a-beta,8a-alpha))-
brn 2054148
sclareol (natural)
1-naphthalenepropanol, alpha-ethenyldecahydro-2-hydroxy-alpha,2,5,5,8a-pentamethyl-, (1theta-(1alpha(theta),2beta,4abeta,8aalpha))-
1-naphthalenepropanol, alpha-ethenyldecahydro-2-hydroxy-alpha,2,5,5,8a-pentamethyl-, (alphar,1r,2r,4as,8as)-
(1r-(1alpha(r*),2beta,4abeta,8aalpha))-2-hydroxy-alpha,2,5,5,8a-pentamethyl-alpha-vinyldecahydronaphthalene-1-propan-1-ol
(13r)-labd-14-ene-8,13-diol
einecs 208-194-0
C09183
515-03-7
sclareol
(13r)-labd-14-ene-8alpha,13-diol
1-naphthalenepropanol, alpha-ethenyldecahydro-2-hydroxy-alpha,2,5,5,8a-pentamethyl-, (alphar,1r,2r,4as,8as)-: (1r,2r,4as,8as)-1-[(3r)-3-hydroxy-3-methylpent-4-en-1-yl]-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol
(1r,2r,4as,8as)-1-[(3r)-3-hydroxy-3-methyl-pent-4-enyl]-2,5,5,8a-tetramethyl-decalin-2-ol
sclareol, 98%
(1r,2r,4as,8as)-1-[(3r)-3-hydroxy-3-methylpent-4-en-1-yl]-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol
CHEBI:9053 ,
labd-14-ene-8,13-diol
CHEMBL294740
LMPR0104030010
(1r,2r,4as,8as)-1-[(3r)-3-hydroxy-3-methylpent-4-en-1-yl]-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol labd-14-ene-8,13-diol
(1r,2r,4as,8as)-1-[(3r)-3-hydroxy-3-methylpent-4-enyl]-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1h-naphthalen-2-ol
dtxsid0047111 ,
tox21_302727
dtxcid8027111
cas-515-03-7
NCGC00256908-01
A828631
(1r,2r,4as,8as)-1-((r)-3-hydroxy-3-methylpent-4-en-1-yl)-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol
b607np0q8y ,
unii-b607np0q8y
4-06-00-05554 (beilstein handbook reference)
(1r,2r,8as)-decahydro-1-(3-hydroxy-3-methyl-4-pentenyl)-2,5,5,8a-tetramethyl-2-naphthol
fema no. 4502
sclareol [inci]
1-naphthalenepropanol, .alpha.-ethenyldecahydro-2-hydroxy-.alpha.,2,5,5,8a-pentamethyl-, (.alpha.r,1r,2r,4as,8as)-
(-)-sclareol
1-naphthalenepropanol, .alpha.-ethenyldecahydro-2-hydroxy-.alpha.,2,5,5,8a-pentamethyl-, (1r-(1.alpha.(r*),2.beta.,4a.beta.,8a.alpha.))-
SCHEMBL873931
AKOS025310185
XVULBTBTFGYVRC-HHUCQEJWSA-N
AC-34890
S0916
scareol
mfcd00869558
sclareol, analytical standard
(1r,2r,4as,8as)-1-[(3r)-3-hydroxy-3-methylpent-4-en-1-yl]-2,5,5,8a-tetramethyl-decahydronaphthalen-2-ol
(1r,2r,8as)-1-((r)-3-hydroxy-3-methylpent-4-enyl)-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol
HY-N0128
AS-14857
Q63396017
CS-0007834
(1r,2r,4as,8ar)-1-[(3r)-3-hydroxy-3-methylpent-4-enyl]-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1h-naphthalen-2-ol
sclareol 1000 microg/ml in acetone
(1r-(1?(r*),2?,4a?,8a?))-?-ethylenedecahydro-2-hydroxy-?,2,5,5,8a-pentamethyl-1-naphthalenepropanol; (-)-sclareol
labd-14-ene-8alpha, 13beta-diol
(1r,2r,4as,8as)-1-((3r)-3-hydroxy-3-methylpent-4-en-1-yl)-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol
1-naphthalenepropanol, alpha-ethenyldecahydro-2-hydroxy-alpha,2,5,5,8a-pentamethyl-, (1r-(1alpha(r*),2beta,4abeta,8aalpha))-

Research Excerpts

Overview

Sclareol is a labdane diterpene which carries on a broad range of biological activities. It is a key starting material with significant market interest for synthesizing high-value ambroxide, a sustainable substitute for ambergris in high-end fragrances.

ExcerptReferenceRelevance
"Sclareol (1) is a natural fragrance compound used widely in the cosmetic and food industries. "( Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
Huang, GJ; Pan, CH; Wu, CH, 2012
)
3.26
"Sclareol is a labdane diterpene which carries on a broad range of biological activities. "( SCLAREIN (SCLAREol contained in zeIN) nanoparticles: Development and characterization of an innovative natural nanoformulation.
Bonacci, S; Cosco, D; Fresta, M; Gagliardi, A; Iriti, G; Procopio, A; Voci, S, 2021
)
2.47
"Sclareol glycol is a key starting material with significant market interest for synthesizing high-value ambroxide, a sustainable substitute for ambergris in high-end fragrances. "( Probing the Biotransformation Process of Sclareol by Resting Cells of
Diao, M; Li, C; Li, J; Lu, J; Xie, N, 2022
)
2.43
"Sclareol is a natural product (initially isolated from the leaves and flowers of Salvia Sclarea) that possesses immune-regulation and anti-inflammatory effects, but its role in osteoclastic formation and function as well as the PMO remains unknown."( Sclareol prevents ovariectomy-induced bone loss in vivo and inhibits osteoclastogenesis in vitro via suppressing NF-κB and MAPK/ERK signaling pathways.
Bai, X; Jennifer, T; Jin, H; Liu, Q; Miao, J; Qiu, H; Shao, Z; Wang, C; Wang, Q; Wang, X; Xu, J; Zhang, Z, 2019
)
2.68
"Sclareol (sclarcol) is an organic compound extracted from sage clary plants. "( The study of sclareol in inhibiting proliferation of osteosarcoma cells by apoptotic induction and loss of mitochondrial membrane potential.
Deng, B; Duan, G; Hou, S; Ji, J, 2018
)
2.29
"Sclareol is a bioactive hydrophobic diterpene in the essential oil isolated from Salvia sclarea (Fam. "( Sclareol-loaded lipid nanoparticles improved metabolic profile in obese mice.
Barcelos, LDS; Cerri, GC; Feltenberger, JD; Ferreira, LAM; Lelis, DF; Lima, LCF; Monteiro-Junior, RS; Mussi, SV; Santos, RASD; Santos, SHS, 2019
)
3.4
"Sclareol is an important intermediate for ambroxide synthesis industries. "( Comparative proteomic analyses of Hyphozyma roseonigra ATCC 20624 in response to sclareol.
Hua, D; Qin, J; Wang, X; Yao, Q; Zhang, X, 2019
)
2.18
"Sclareol is a phytochemical used in people's diet in Southeast Asia."( Sclareol reduces CD4+ CD25+ FoxP3+ Treg cells in a breast cancer model in vivo.
Hassan, ZM; Noori, S; Salehian, O, 2013
)
3.28
"Sclareol is a member of labdane type diterpenes mostly used as fragrance ingredient. "( [Engineering Saccharomyces cerevisiae for sclareol production].
Liu, W; Shen, H; Yang, W; Zhao, ZK; Zhou, Y, 2013
)
2.1
"Sclareol is a natural product initially isolated form Salvia sclarea which possesses immune-regulation and anti-inflammatory activities. "( Sclareol exerts anti-osteoarthritic activities in interleukin-1β-induced rabbit chondrocytes and a rabbit osteoarthritis model.
Huang, Y; Santoso, MB; Wu, LD; Zhong, Y, 2015
)
3.3
"Sclareol is a natural fragrance compound that is used widely in the cosmetic and food industries. "( Sclareol ameliorate lipopolysaccharide-induced acute lung injury through inhibition of MAPK and induction of HO-1 signaling.
Deng, JS; Hsieh, YH; Huang, GJ; Huang, SS; Liao, JC; Pan, HP, 2017
)
3.34
"Sclareol is a diterpene natural product of high value for the fragrance industry. "( Discovery and functional characterization of two diterpene synthases for sclareol biosynthesis in Salvia sclarea (L.) and their relevance for perfume manufacture.
Bohlmann, J; Caniard, A; Cohade, A; Legendre, L; Legrand, S; Magnard, JL; Valot, N; Zerbe, P, 2012
)
2.05
"Sclareol is a high-value natural product obtained by solid/liquid extraction of clary sage (Salvia sclarea L.) inflorescences. "( Extracellular localization of the diterpene sclareol in clary sage (Salvia sclarea L., Lamiaceae).
Audran, A; Baudino, S; Caissard, JC; Delbecque, C; Garry, PP; Jullien, F; Legrand, S; Magnard, JL; Moja, S; Nicolé, F; Olivier, T; Palle, S; Valot, N, 2012
)
2.08
"Sclareol is a labdane-type diterpene that has demonstrated a significant cytotoxic activity against human leukemic cell lines. "( Labd-14-ene-8,13-diol (sclareol) induces cell cycle arrest and apoptosis in human breast cancer cells and enhances the activity of anticancer drugs.
Alevizopoulos, K; Demetzos, C; Dimas, K; Hatziantoniou, S; Pantazis, P; Papadaki, M; Tsimplouli, C, 2006
)
2.09

Effects

ExcerptReferenceRelevance
"Sclareol has been widely studied due to its anti-inflammatory and antioxidant effects."( Sclareol-loaded lipid nanoparticles improved metabolic profile in obese mice.
Barcelos, LDS; Cerri, GC; Feltenberger, JD; Ferreira, LAM; Lelis, DF; Lima, LCF; Monteiro-Junior, RS; Mussi, SV; Santos, RASD; Santos, SHS, 2019
)
2.68

Actions

ExcerptReferenceRelevance
"Sclareol may increase the expression of CCN1 through inhibiting the MAPK pathway, thereby inhibiting osteoclast differentiation and attenuating bone resorption."( Sclareol inhibits RANKL-induced osteoclastogenesis and promotes osteoblastogenesis through promoting CCN1 expression via repressing the MAPK pathway.
Li, L; Li, X; Wang, Y; Zhao, F; Zhou, S, 2021
)
2.79

Treatment

Sclareol treatment significantly alleviated renal dysfunction, fibrosis, and inflammatory cytokine levels in a dose-dependent manner in diabetic mice. Sclarel treatment led to significant decrease in the levels of p-MEK and p-ERK. Pretreatment with sClareol noticeably improved the LPS-induced histological alterations and edema in lung tissue.

ExcerptReferenceRelevance
"Sclareol treatment significantly alleviated renal dysfunction, fibrosis, and inflammatory cytokine levels in a dose-dependent manner in diabetic mice."( Sclareol ameliorates hyperglycemia-induced renal injury through inhibiting the MAPK/NF-κB signaling pathway.
Han, X; Liang, G; Ren, J; Shi, Q; Tu, Y; Wang, Y; Wei, J; Ying, H; Zhang, J; Zhang, Y; Zhou, L, 2022
)
2.89
"Sclareol treatment led to significant decrease in the levels of p-MEK and p-ERK."( Naturally Occurring Sclareol Diterpene Augments the Chemosensitivity of Human Hela Cervical Cancer Cells by Inducing Mitochondrial Mediated Programmed Cell Death, S-Phase Cell Cycle Arrest and Targeting Mitogen-Activated Protein Kinase (MAPK)/Extracellula
Hongjuan, M; Li, W; Minglian, L; Ping, Z; Xuemei, G; Yi, H; Zhongxiang, Z, 2020
)
1.6
"Pretreatment with sclareol noticeably improved the LPS-induced histological alterations and edema in lung tissue."( Sclareol ameliorate lipopolysaccharide-induced acute lung injury through inhibition of MAPK and induction of HO-1 signaling.
Deng, JS; Hsieh, YH; Huang, GJ; Huang, SS; Liao, JC; Pan, HP, 2017
)
2.22

Bioavailability

ExcerptReferenceRelevance
" The foremost obstacle to an efficacious application and use of this molecule is its unfavorable bioavailability due to its poor aqueous solubility."( Sclareol-loaded hyaluronan-coated PLGA nanoparticles: Physico-chemical properties and in vitro anticancer features.
Cilurzo, F; Cosco, D; Fresta, M; Mare, R; Paolino, D; Salvatici, MC, 2019
)
1.96
" However, its poor water solubility and bioavailability are the foremost drawbacks that limit its application in therapeutics."( SCLAREIN (SCLAREol contained in zeIN) nanoparticles: Development and characterization of an innovative natural nanoformulation.
Bonacci, S; Cosco, D; Fresta, M; Gagliardi, A; Iriti, G; Procopio, A; Voci, S, 2021
)
1.02

Dosage Studied

ExcerptRelevanceReference
" Arthritic DBA/1J mice were dosed with 5 and 10 mg/kg sclareol intraperitoneally every other day over 21 days."( Therapeutic Potential of Sclareol in Experimental Models of Rheumatoid Arthritis.
Hsieh, MC; Lehman, CW; Li, S; Lien, CZ; Lin, CC; Lin, SC; Tsai, SW; Wang, SP, 2018
)
1.03
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
fragranceA substance, extract, or preparation for diffusing or imparting an agreeable or attractive smell.
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
labdane diterpenoidAny diterpenoid with a labdane skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency54.94103.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency61.13060.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency48.96620.173734.304761.8120AID1346924
SMAD family member 3Homo sapiens (human)Potency48.96620.173734.304761.8120AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency63.61690.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency52.64360.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743053; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency68.58960.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency47.94780.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency20.47660.001022.650876.6163AID1224893
progesterone receptorHomo sapiens (human)Potency27.30600.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency58.63660.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency48.87990.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency44.80320.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency49.89390.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency55.18400.375827.485161.6524AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency9.68850.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency60.83940.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency58.19650.001024.504861.6448AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency32.55570.001019.414170.9645AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency57.41860.023723.228263.5986AID743222; AID743223; AID743241
caspase-3Homo sapiens (human)Potency68.58960.013326.981070.7614AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency54.48270.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency18.96730.001628.015177.1139AID1224843; AID1224895
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency22.94410.154917.870243.6557AID1346877; AID1346891
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency61.644819.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency34.57130.057821.109761.2679AID1159526; AID1159528
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency32.77650.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency51.95360.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency76.95880.000627.21521,122.0200AID743202
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency61.13060.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency68.58960.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency61.13060.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID94066Minimum inhibitory concentration against Klebsiella pneumoniae (ATCC 13883)2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Structure elucidation and conformational properties of a novel bioactive clerodane diterpene using a combination of high field NMR spectroscopy, computational analysis and X-ray diffraction.
AID159918Minimum inhibitory concentration against Pseudomonas aeruginosa2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Structure elucidation and conformational properties of a novel bioactive clerodane diterpene using a combination of high field NMR spectroscopy, computational analysis and X-ray diffraction.
AID1203694Induction of autophagy in human PC3 cells at 100 to 300 nM after 24 hrs2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID647946Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced decrease in GPx activity in liver at 5 mg/kg, ip administered 30 mins before carrageenan challenge measured after 5 hrs2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID647936Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 30 mins before carrageenan challenge measured after 3 hrs by plethysmometer analysis2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID1203693Induction of apoptosis in human PC3 cells at 100 to 300 nM after 24 hrs2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID647940Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced iNOS protein expression in paw at 10 mg/kg, ip administered 30 mins before carrageenan challenge by Western blotting relative to control2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID1355437Transactivation of human Gal4-fused RXRbeta LBD expressed in HEK293T cells after 12 to 14 hrs by dual-glo luciferase assay2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
Computer-Assisted Discovery of Retinoid X Receptor Modulating Natural Products and Isofunctional Mimetics.
AID1203692Effect on Beclin-1 protein expression in human PC3 cells at 0.2 to 0.3 uM after 24 hrs by immunoblotting method2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID1203711Induction of apoptosis in human PC3 cells assessed as caspase-3 cleavage at 300 nM after 24 hrs by Western blotting method2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID1203705Inhibition of Akt in human PC3 cells assessed as reduction in mTOR S2448 phosphorylation at 0.1 to 0.3 uM after 24 hrs by Western blotting method2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID70151Minimum inhibitory concentration against Escherichia coli (ATCC 25922)2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Structure elucidation and conformational properties of a novel bioactive clerodane diterpene using a combination of high field NMR spectroscopy, computational analysis and X-ray diffraction.
AID647944Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced decrease in CAT activity in liver at 5 mg/kg, ip administered 30 mins before carrageenan challenge measured after 5 hrs2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID200824In vitro cytotoxicity of compound was measured on human gastric adenocarcinoma (SNU-1) cells.1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
A concise synthesis and in vitro cytotoxicity of new labdane diterpenes.
AID647933Cytotoxicity against human PBMC2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID92582Percentage inhibition against growth factor induced tube formation by human umbilical vein endothelial cells (HUVEC) at 10 ug/mL concentration; NT: Not tested2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
A study on the synthesis of antiangiogenic (+)-coronarin A and congeners from (+)-sclareolide.
AID1203681Cytotoxicity against human PC3 cells after 48 hrs by MTT assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID1203689Induction of autophagy in human PC3 cells at 100 to 300 nM after 24 hrs by acridine orange staining based fluorescence microscopy2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID39128In vitro cytotoxicity of compound was measured on murine melanoma (B16) cells.1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
A concise synthesis and in vitro cytotoxicity of new labdane diterpenes.
AID647934Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced iNOS expression at 5 to 10 ug/ml by Western blotting2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1203691Effect on SQSTM1/P62 protein expression in human PC3 cells at 0.2 to 0.3 uM after 24 hrs by immunoblotting method2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID647943Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced malondialdehyde level in paw at 10 mg/kg, ip administered 30 mins before carrageenan challenge by TRARS method2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID1355440Transactivation of human Gal4-fused RXRgamma LBD expressed in HEK293T cells after 12 to 14 hrs by dual-glo luciferase assay2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
Computer-Assisted Discovery of Retinoid X Receptor Modulating Natural Products and Isofunctional Mimetics.
AID1203682Cytotoxicity against human A549 cells after 48 hrs by MTT assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID647937Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced nitric oxide level in paw serum at 1 to 10 mg/kg, ip administered 30 mins before carrageenan challenge measured after 5 hrs by Griess method2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID152272In vitro cytotoxicity of compound was measured on murine lymphocytic leukemia (P-388) cells.1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
A concise synthesis and in vitro cytotoxicity of new labdane diterpenes.
AID92563Growth inhibitory activity against human umbilical vein endothelial cells (HUVEC) proliferation using MTT colorimetric method2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
A study on the synthesis of antiangiogenic (+)-coronarin A and congeners from (+)-sclareolide.
AID1203704Inhibition of Akt S473 phosphorylation in human PC3 cells at 0.1 to 0.3 uM after 24 hrs by Western blotting method2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID1203690Effect on MAP1LC3 I/II protein expression in human PC3 cells at 0.2 to 0.3 uM after 24 hrs by immunoblotting method2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID647938Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced TNFalpha level in paw serum at 1 mg/kg, ip administered 30 mins before carrageenan challenge measured after 5 hrs by ELISA2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID206049Minimum inhibitory concentration against Staphylococcus epidermidis (ATCC 12228)2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Structure elucidation and conformational properties of a novel bioactive clerodane diterpene using a combination of high field NMR spectroscopy, computational analysis and X-ray diffraction.
AID647945Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced decrease in SOD activity in liver at 5 mg/kg, ip administered 30 mins before carrageenan challenge measured after 5 hrs2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID647935Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced COX2 expression at 5 to 10 ug/ml by Western blotting2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID206516Minimum inhibitory concentration against Staphylococcus hominis (ATCC 27844)2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Structure elucidation and conformational properties of a novel bioactive clerodane diterpene using a combination of high field NMR spectroscopy, computational analysis and X-ray diffraction.
AID1203683Cytotoxicity against human HeLa cells after 48 hrs by MTT assay2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.
AID647928Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated 1 hr before LPS challenge measured after 24 hrs by Griess method2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID647930Cytotoxicity against human leukemia cells2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID647942Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced neutrophil infiltration in paw at 10 mg/kg, ip administered 30 mins before carrageenan challenge2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID647931Cytotoxicity against human breast cancer cells2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID647941Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced COX2 protein expression in paw at 10 mg/kg, ip administered 30 mins before carrageenan challenge by Western blotting relative to control2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID647939Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced malondialdehyde level in paw serum at 1 mg/kg, ip administered 30 mins before carrageenan challenge measured after 5 hrs by TRARS method2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID206640Minimum inhibitory concentration against Staphylococcus aureus (ATCC 6538)2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Structure elucidation and conformational properties of a novel bioactive clerodane diterpene using a combination of high field NMR spectroscopy, computational analysis and X-ray diffraction.
AID1525012Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite viability incubated for 48 hrs by APAD colorimetric test
AID647929Cytotoxicity against LPS-stimulated mouse RAW264.7 cells assessed as cell viability at 10 ug/ml treated 1 hr before LPS challenge measured after 24 hrs by MTT assay2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
AID647932Cytotoxicity against human HCT116 cells2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ-carrageenan-induced paw edema model.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (103)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (4.85)18.7374
1990's5 (4.85)18.2507
2000's20 (19.42)29.6817
2010's49 (47.57)24.3611
2020's24 (23.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.59 (24.57)
Research Supply Index4.67 (2.92)
Research Growth Index5.22 (4.65)
Search Engine Demand Index67.63 (26.88)
Search Engine Supply Index2.85 (0.95)

This Compound (35.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.83%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other103 (97.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]